- Home
- EDAP vs BTAI Comparison
EDAP vs BTAI Comparison
Compare EDAP & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDAP
- BTAI
- Stock Information
- Founded
- EDAP 1979
- BTAI 2017
- Country
- EDAP France
- BTAI United States
- Employees
- EDAP N/A
- BTAI N/A
- Industry
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- EDAP Health Care
- BTAI Health Care
- Exchange
- EDAP Nasdaq
- BTAI Nasdaq
- Market Cap
- EDAP 46.7M
- BTAI 48.3M
- IPO Year
- EDAP 1997
- BTAI 2018
- Fundamental
- Price
- EDAP $2.25
- BTAI $2.36
- Analyst Decision
- EDAP Buy
- BTAI Buy
- Analyst Count
- EDAP 3
- BTAI 5
- Target Price
- EDAP $8.50
- BTAI $32.80
- AVG Volume (30 Days)
- EDAP 62.9K
- BTAI 1.3M
- Earning Date
- EDAP 11-06-2025
- BTAI 11-13-2025
- Dividend Yield
- EDAP N/A
- BTAI N/A
- EPS Growth
- EDAP N/A
- BTAI N/A
- EPS
- EDAP N/A
- BTAI N/A
- Revenue
- EDAP $74,008,221.00
- BTAI $868,000.00
- Revenue This Year
- EDAP N/A
- BTAI N/A
- Revenue Next Year
- EDAP N/A
- BTAI $614.78
- P/E Ratio
- EDAP N/A
- BTAI N/A
- Revenue Growth
- EDAP 1.56
- BTAI N/A
- 52 Week Low
- EDAP $1.21
- BTAI $1.17
- 52 Week High
- EDAP $3.08
- BTAI $13.28
- Technical
- Relative Strength Index (RSI)
- EDAP 51.26
- BTAI 38.39
- Support Level
- EDAP $2.09
- BTAI $2.26
- Resistance Level
- EDAP $2.79
- BTAI $2.76
- Average True Range (ATR)
- EDAP 0.21
- BTAI 0.18
- MACD
- EDAP -0.02
- BTAI 0.01
- Stochastic Oscillator
- EDAP 36.91
- BTAI 13.82
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.